FGF23 effects on the heart —levels, time, source, and context matter
Fibroblast growth factor 23 (FGF23) has appeared as a hormone that is massively elevated in patients with chronic kidney disease. Whether FGF23 is a risk factor that associates with cardiac pathologies and cardiovascular mortality, as suggested by a variety of clinical studies, or additionally acts as a causative factor that induces cardiac injury, as more recently indicated by cell culture and animal studies, is under debate and the center of many ongoing experimental studies.
Source: Kidney International - Category: Urology & Nephrology Authors: Christian Faul Tags: Commentary Source Type: research
More News: Cardiology | Cardiovascular | Chronic Kidney Disease | Heart | Hormones | Study | Urology & Nephrology